| NCT06602193 | Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD) | RECRUITING | PHASE2 | 2024-10-24 | 2028-02-28 | 2026-04-30 |
| NCT06281158 | A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants | COMPLETED | PHASE1 | 2024-03-01 | 2024-04-30 | 2024-04-30 |
| NCT06181136 | Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A) | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2023-12-07 | 2028-08 | 2028-08 |
| NCT06075537 | An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007 | ENROLLING_BY_INVITATION | PHASE2, PHASE3 | 2023-09-20 | 2027-06 | 2027-06 |
| NCT05371613 | A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II) | RECRUITING | PHASE2, PHASE3 | 2022-07-21 | 2027-12 | 2027-12 |
| NCT05450549 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy Participants | COMPLETED | PHASE1 | 2022-07-14 | 2023-06-08 | 2023-06-08 |
| NCT05262023 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN) | RECRUITING | PHASE1, PHASE2 | 2022-02-01 | 2028-11 | 2026-12 |
| NCT05006352 | A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis | COMPLETED | PHASE1 | 2021-08-11 | 2024-06-05 | 2022-12-15 |
| NCT04581772 | A Study to Evaluate the Bioavailability and Safety of DNL343 in Healthy Volunteers | COMPLETED | PHASE1 | 2020-12-23 | 2021-06-04 | 2021-06-04 |
| NCT04251026 | A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2020-07-16 | 2031-02 | 2031-02 |
| NCT04268784 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL343 in Healthy Volunteers | COMPLETED | PHASE1 | 2020-02-20 | 2021-08-03 | 2021-08-03 |
| NCT03757325 | Study to Evaluate DNL747 in Subjects With Alzheimer's Disease | COMPLETED | PHASE1 | 2019-02-13 | 2019-12-05 | 2019-12-05 |
| NCT03710707 | Study to Evaluate DNL201 in Subjects With Parkinson's Disease | COMPLETED | PHASE1 | 2018-12-04 | 2019-12-06 | 2019-12-06 |
| NCT04557800 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Healthy Volunteers | COMPLETED | PHASE1 | 2017-11-16 | 2021-02-19 | 2021-02-19 |
| NCT04551534 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Healthy Volunteers | COMPLETED | PHASE1 | 2017-06-01 | 2018-08-08 | 2018-08-08 |